You are here: Home » 2025 » May » Archives for 28th

CGC DEADLINE: ROSEN, HIGHLY REGARDED INVESTOR RIGHTS COUNSEL, Encourages Canopy Growth Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action – CGC

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Canopy Growth Corporation (NASDAQ: CGC) between May 30, 2024 and February 6, 2025, both dates inclusive (the “Class Period”), of the important June 3, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Canopy Growth securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Canopy Growth class action, go to https://rosenlegal.com/submit–form/?case_id=16092 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 3, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Canopy Growth had incurred significant costs producing Claybourne Co. (“Claybourne”) pre–rolled joints in connection with the Claybourne product launch in Canada; (2) the foregoing costs, in addition to certain indirect costs that Canopy Growth incurred in connection with its Storz & Bickel vaporizer devices, were likely to have a significant negative impact on the Canopy Growth’s gross margins and overall financial results; (3) accordingly, defendants had overstated the efficacy of Canopy Growth’s cost reduction measures and the health of its gross margins while downplaying issues with the same; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Canopy Growth class action, go to https://rosenlegal.com/submit–form/?case_id=16092 call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686–1060
        Toll Free: (866) 767–3653
        Fax: (212) 202–3827
        [email protected]
        www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9459534)

BBAI DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages BigBear.ai Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action – BBAI

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BigBear.ai Holdings, Inc. (NYSE: BBAI) between March 31, 2022 and March 25, 2025, both dates inclusive (the “Class Period”), of the important June 10, 2025 lead plaintiff deadline.

SO WHAT: If you purchased BigBear.ai securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the BigBear.ai class action, go to https://rosenlegal.com/submit–form/?case_id=37621 or call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 10, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) BigBear.ai maintained deficient accounting review policies related to the reporting and disclosure of certain non–routine, unusual, or complex transactions; (2) as a result, BigBear.ai incorrectly determined that the conversion option within the 2026 Convertible Notes qualified for the derivative scope exception under Accounting Standards Codification (“ASC”) 815–40 and failed to bifurcate the conversion option as required by ASC 815–15; (3) accordingly, BigBear.ai had improperly accounted for the 2026 Convertible Notes; (4) the foregoing error caused BigBear.ai to misstate various items in several of BigBear.ai’s previously issued financial statements; (5) as a result, these financial statements were inaccurate and would likely need to be restated; (6) BigBear.ai would require extra time and expense to correct the inaccurate financial statements, thereby increasing the risk that BigBear.ai would be unable to timely file certain financial reports with the SEC; and (7) as a result, BigBear.ai’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the BigBear.ai class action, go to https://rosenlegal.com/submit–form/?case_id=37621 or call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686–1060
        Toll Free: (866) 767–3653
        Fax: (212) 202–3827
        [email protected]
        www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9459512)

BKKT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Bakkt Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 2 Deadline in Securities Class Action – BKKT

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bakkt Holdings, Inc. (NYSE: BKKT) between March 25, 2024 and March 17, 2025, both dates inclusive (the “Class Period”), of the important June 2, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Bakkt securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Bakkt class action, go to https://rosenlegal.com/submit–form/?case_id=5546 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 2, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) misrepresented the stability and/or diversity of its crypto services revenue; (2) failed to disclose Bakkt’s Crypto services revenue was substantially dependent on a single contract with Webull; (3) misrepresented its ability to maintain key client relationships; and (4) as a result of the foregoing, defendants’ positive statements about Bakkt’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Bakkt class action, go to https://rosenlegal.com/submit–form/?case_id=5546 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
[email protected]
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9459497)

Nyxoah to Present at the Jefferies Global Healthcare Conference

Nyxoah to Present at the Jefferies Global Healthcare Conference

Mont–Saint–Guibert, Belgium – May 28, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies Global Healthcare Conference, which takes place June 3 – 5, 2025 in New York.

Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate presentation on Tuesday, June 4, 2025, at 4:55pm ET. A webcast of the presentation will be available in the Events section of Nyxoah’s Investor Relations website. The Company will be available for 1×1 meetings with institutional investors.

Nyxoah’s Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward–looking statements
Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; receipt of FDA approval; satisfactory completion of a manufacturing facilities, methods and controls review, and the anticipated timing of the foregoing; entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20–F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward–looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

Attachment


GLOBENEWSWIRE (Distribution ID 1001099538)

Nyxoah Participera à la Jefferies Global Healthcare Conference

Nyxoah Participera à la Jefferies Global Healthcare Conference

Mont–Saint–Guibert, Belgique – 28 mai 2025, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») une société de technologie médicale développant des alternatives thérapeutiques innovantes pour l'apnée obstructive du sommeil (AOS) par la neuromodulation, a annoncé aujourd'hui qu’elle participera à la Jefferies Global Healthcare Conference, qui aura lieu du 3 au 5 juin 2025 à New York.

Olivier Taelman, Chief Executive Officer de Nyxoah, présentera une mise à jour de l’entreprise le mardi 4 juin 2025 à 16h55 ET. La diffusion Web sera disponible sur la page Events du site Web des relations avec les investisseurs de Nyxoah. La Société sera également disponible pour des réunions en tête–à–tête avec les investisseurs institutionnels.

La présentation aux investisseurs de Nyxoah est accessible dans la section Shareholder Information de la page Company’s Investor Relations.

A propos de Nyxoah

Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La vision de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

À la suite de la finalisation probante de l’étude BLAST OSA, le système Genio® a reçu le marquage européen CE en 2019. Nyxoah a réalisé avec succès deux IPO : l’une sur Euronext Bruxelles en septembre 2020 et l’autre sur le NASDAQ en juillet 2021. Grâce aux résultats positifs de l'étude BETTER SLEEP, Nyxoah a reçu le marquage CE pour l’extension de ses indications thérapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thérapies concurrentes sont actuellement contre–indiquées. En outre, la Société a annoncé les résultats positifs de l'étude pivot DREAM IDE.

Pour plus d’informations, visitez www.nyxoah.com

Attention – Marquage CE depuis 2019. Dispositif de recherche aux États–Unis. Limité à un usage expérimental aux États–Unis par la loi fédérale américaine.

Déclarations Prospectives

Certaines déclarations, croyances et opinions contenues dans le présent communiqué de presse sont de nature prospective et reflètent les attentes actuelles de la Société ou, le cas échéant, des administrateurs ou de la direction de la Société concernant le système Genio®, les études cliniques prévues et en cours sur le système Genio®, les avantages potentiels du système Genio®, les objectifs de Nyxoah concernant le développement, la voie réglementaire et l'utilisation potentielle du système Genio®, l'obtention de l'approbation de la FDA, l'achèvement satisfaisant de l'examen des installations de fabrication, des méthodes et des contrôles, et le calendrier prévu pour ce qui précède, l'entrée sur le marché américain, ainsi que les résultats d'exploitation, la situation financière, les liquidités, les performances, les perspectives, la croissance et les stratégies de la Société. De par leur nature, les déclarations prévisionnelles impliquent un certain nombre de risques, d'incertitudes, d'hypothèses et d'autres facteurs qui pourraient faire en sorte que les résultats ou les événements réels diffèrent matériellement de ceux exprimés ou sous–entendus dans les déclarations prévisionnelles. Ces risques, incertitudes, hypothèses et facteurs pourraient avoir une incidence négative sur les résultats et les effets financiers des plans et des événements décrits dans le présent document. En outre, ces risques et incertitudes comprennent, sans s'y limiter, les risques et incertitudes énoncés dans la section « Facteurs de risque » du rapport annuel de la Société sur le formulaire 20–F pour l'exercice clos le 31 décembre 2024, déposé auprès de la Securities and Exchange Commission (« SEC ») le 20 mars 2025, et des rapports ultérieurs que la Société dépose auprès de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les événements, les performances ou les résultats réels diffèrent de manière significative de tout développement anticipé. Les déclarations prospectives contenues dans le présent communiqué de presse concernant des tendances ou des activités passées ne constituent pas des garanties de performances futures et ne doivent pas être considérées comme une déclaration selon laquelle ces tendances ou activités se poursuivront à l'avenir. En outre, même si les résultats ou développements réels sont conformes aux déclarations prospectives contenues dans le présent communiqué de presse, ces résultats ou développements peuvent ne pas être représentatifs des résultats ou développements des périodes futures. Aucune déclaration ou garantie n'est donnée quant à l'exactitude ou à la justesse de ces déclarations prospectives. En conséquence, la Société décline expressément toute obligation ou tout engagement de publier des mises à jour ou des révisions des déclarations prospectives contenues dans le présent communiqué de presse à la suite d'un changement des attentes ou d'un changement des événements, conditions, hypothèses ou circonstances sur lesquels ces déclarations prospectives sont basées, sauf si la loi ou la réglementation l'exige expressément. Ni la Société, ni ses conseillers ou représentants, ni aucune de ses filiales, ni les dirigeants ou employés de ces personnes ne garantissent que les hypothèses sous–jacentes à ces déclarations prospectives sont exemptes d'erreurs et n'acceptent aucune responsabilité quant à l'exactitude future des déclarations prospectives contenues dans ce communiqué de presse ou quant à la survenance effective des développements prévus. Vous ne devriez pas accorder une confiance excessive aux déclarations prospectives, qui ne sont valables qu'à la date du présent communiqué de presse.

Contacts :

Nyxoah
John Landry, CFO
[email protected]

Pièce jointe


GLOBENEWSWIRE (Distribution ID 1001099538)

gategroup Successfully Prices Refinancing Transaction, Paving the Way for Growth and Market Expansion

gategroup Holding AG (“gategroup”) is pleased to announce the successful pricing of its comprehensive refinancing package, comprising two term loans of EUR 675 million and USD 500 million, both with a tenure of 7 years, and a CHF 300 million multicurrency revolving credit facility (the “new financing”) with a tenure of 6.5 years. The transaction was significantly oversubscribed and priced at the tighter end of guidance – strongly underscoring market confidence in gategroup’s strategy and performance.

This transaction represents gategroup’s debut as a Term Loan B (TLB) issuer, and the company is pleased to have attracted strong demand from leading global institutional investors. The level of interest received highlights the trust placed in gategroup’s credit profile, operational resilience, and future growth potential.

The New Financing is backed by a syndicate of top–tier global financial institutions and supports the refinancing of existing loans, notably the EUR 250 million Term Loan A and the CHF 415 million revolving credit facility, while also improving liquidity and flexibility.

“This successful refinancing marks a pivotal milestone for us,” said Christoph Schmitz, Chief Executive Officer of gategroup. “The broad–based support from a large group of premier banking partners and top global funds is a powerful endorsement of our business and strategy. This transaction diversifies gategroup´s funding base and allows us to invest in long–term initiatives, expand our global footprint, and further elevate our market–leading services in airline catering and hospitality.”

With the anticipated upgrade in its corporate credit rating to B2 (stable) / B+ (stable) by Moody’s and S&P Global respectively, gategroup gains improved access to capital markets. The refinancing significantly enhances the company’s capital structure and positions it for sustainable growth and value creation.

Urs Schwendinger, Chief Financial Officer of gategroup, added: “We are extremely pleased with the outcome of this transaction, which despite volatile market conditions has achieved several notable milestones among deals launched post–the US tariff announcements, including the largest cross–border loan issuance, largest debut issuance, and in its segment and rating universe, the largest new money loan deal and the largest Swiss issuance.”

For media and investor inquiries, please contact:

[email protected]

[email protected]

About gategroup

gategroup is the global leader in airline catering, retail–on–board, and hospitality products and services. Headquartered in Zurich, Switzerland, gategroup operates over 200 units in more than 60 countries, delivering culinary and retail excellence to passengers across all continents. Learn more at www.gategroup.com.

gategroup schließt Refinanzierung erfolgreich ab und ebnet den Weg für weiteres Wachstum und Marktexpansion 

Die gategroup Holding AG („gategroup“) freut sich, den erfolgreichen Abschluss und die Preisfestsetzung ihres umfassenden Refinanzierungspakets bekannt zu geben. Die neue Finanzierung umfasst zwei Term Loan B Instrumente in Höhe von EUR 675 Mio. und USD 500 Mio., beide mit einer Laufzeit von 7 Jahren, und eine revolvierende Kreditfazilität in Höhe von CHF 300 Mio. mit einer Laufzeit von 6,5 Jahren (die „Neue Finanzierung“). Die Transaktion war deutlich überzeichnet und wurde zu attraktiven Konditionen abgeschlossen, was das Vertrauen der Märkte in gategroups Strategie und finanzielle Stärke unterstreicht.

Mit dieser Emission tritt gategroup erstmals als Term Loan B Emittentin auf, und das Unternehmen freut sich über die starke Nachfrage von führenden globalen institutionellen Investoren. Das große Interesse unterstreicht das Vertrauen in gategroups Marktposition, die operative Leistungsfähigkeit und das zukünftige Wachstumspotenzial.

Die Neue Finanzierung wird von einem Konsortium erstklassiger internationaler Finanzinstitute unterstützt und dient der Refinanzierung bestehender Kredite, insbesondere des EUR 250 Mio. Term Loan A und der existierenden revolvierenden Kreditfazilität in Höhe von CHF 415 Mio. Sie verbessert gleichzeitig die Liquidität und Flexibilität der Gruppe. 

„Diese erfolgreiche Refinanzierung ist ein entscheidender Meilenstein für uns“, sagt Christoph Schmitz, Chief Executive Officer von gategroup. „Die breite Unterstützung durch eine große Gruppe führender Bankenpartner und globaler Top–Fonds sind ein starkes Signal für unser Geschäft, unsere Kunden und unsere Strategie. Die Transaktion schafft neue Optionen und ermöglicht es uns in langfristige Projekte zu investieren, unsere globale Präsenz auszubauen und unsere marktführenden Dienstleistungen im Bereich Airline–Catering und Hospitality weiter zu verbessern.“ 

Mit der erwarteten Verbesserung des Unternehmensratings auf B2 (stabil) / B+ (stabil) durch Moody's bzw. S&P Global erhält gategroup einen verbesserten Zugang zu den internationalen Kapitalmärkten. Die Refinanzierung verbessert die Kapitalstruktur des Unternehmens erheblich und positioniert es für nachhaltiges Wachstum und Wertschöpfung.

Urs Schwendinger, Chief Financial Officer von gategroup, fügt hinzu: „Wir sind äußerst zufrieden mit dem Ergebnis dieser Transaktion, die trotz volatiler Marktbedingungen mehrere nennenswerte Merkmale unter den nach der Ankündigung der US–Zölle lancierten Finanztransaktionen aufweist, darunter die größte grenzüberschreitende Term Loan B Emission, die größte Emission einer „First Time“ Emittentin und in ihrem Segment und Rating–Universum die größte Neugelddarlehens–Transaktion“

Für Medien– und Investorenanfragen wenden Sie sich bitte an:

[email protected] 
[email protected]

Über gategroup 
gategroup ist der weltweit führende Anbieter von Airline–Catering, Retail–on–Board und Hospitality–Produkten und Dienstleistungen. Mit Hauptsitz in Zürich, Schweiz, betreibt gategroup über 200 Betriebe in mehr als 60 Ländern, die Passagieren auf allen Kontinenten kulinarische und einzelhandelsbezogene Spitzenleistungen bieten. Erfahren Sie mehr unter www.gategroup.com.


GLOBENEWSWIRE (Distribution ID 1001099569)

CERE DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action – CERE

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that (1) sold or otherwise disposed of the publicly–traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) during the period from October 11, 2023 through August 1, 2024, inclusive (the “Class Period”); (2) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or (3) sold shares of Cerevel stock contemporaneously with Bain Capital’s purchase of shares on or about October 16, 2023, of the important June 3, 2025 lead plaintiff deadline.

SO WHAT: If you sold and/or held Cerevel common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Cerevel class action, go to https://rosenlegal.com/submit–form/?case_id=37997 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 3, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements in connection with Cerevel’s October 16, 2023 secondary stock offering and in its January 18, 2024 proxy statement. As alleged in the complaint, the secondary stock offering was orchestrated by Cerevel’s controlling shareholders, Bain Capital, LP and Pfizer Inc., to allow Bain to increase its position in Cerevel at a deeply discounted price in advance of AbbVie Inc.’s undisclosed forthcoming acquisition of Cerevel. Just 51 days after the offering, Cerevel publicly announced that AbbVie agreed to acquire Cerevel for $45 per share – i.e., nearly double the offering price – and Bain’s discounted purchases from the offering resulted in it receiving a windfall of more than $120 million.

To join the Cerevel class action, go to https://rosenlegal.com/submit–form/?case_id=37997 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
[email protected]
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9459496)

TMCI DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action – TMCI

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the “Class Period”), of the important June 10, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Treace Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Treace Medical class action, go to https://rosenlegal.com/submit–form/?case_id=38284 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 10, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System (the “Lapiplasty”); (2) as a result, Treace Medical’s revenue declined and Treace Medical needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function); and (3) defendants’ positive statements about Treace Medical’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Treace Medical class action, go to https://rosenlegal.com/submit–form/?case_id=38284 call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686–1060
        Toll Free: (866) 767–3653
        Fax: (212) 202–3827
        [email protected]
        www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9459474)

ila Bank et Mastercard s’associent pour lancer une gamme de solutions innovantes et conquérir de nouveaux marchés

MANAMA, Bahreïn, 28 mai 2025 (GLOBE NEWSWIRE) — ila Bank, une entité bancaire soutenue par Bank ABC, s'est associée à Mastercard pour améliorer les services financiers axés sur les consommateurs offerts par la banque, en lançant de nouveaux produits et avantages en matière de voyage et des offres de fidélité.

ila Bank bénéficiera de l'expertise de Mastercard pour lancer un programme de fidélisation qui soutient le style de vie des titulaires de cartes, apportant ainsi une valeur optimisée à travers plusieurs domaines, notamment la restauration, le shopping de luxe, les voyages et les expériences inestimables. La nouvelle gamme de produits s'appuiera également sur des solutions améliorées de prévention de la fraude et de protection de la vie privée pour sécuriser les transactions.

Mohamed Almaraj, PDG d'ila Bank, a déclaré : « ila a toujours adopté une approche centrée sur le client. Nous sommes ainsi fiers d'avoir maintenu notre engagement à offrir des solutions et des expériences centrées sur le client dans une économie qui devient de plus en plus sans numéraire. Cet accord stratégique renforce la promesse d'ila d’offrir des ‘services bancaires qui vous ressemblent’. Ce–disant, renouveler notre engagement avec Mastercard permettra de renforcer notre position de leader dans le secteur des paiements numériques de la région, en proposant la gamme de produits la plus transparente, la plus sécurisée et la plus tournée vers l'avenir, qui offre des avantages premium inégalés. »

Pour sa part, Adam Jones, président de la division de l'Ouest de la péninsule Arabique chez Mastercard, a déclaré : « Conformément à notre engagement commun à promouvoir l'innovation dans l'écosystème numérique, nos liens de longue date avec ila Bank visent à fournir des solutions axées sur le client qui garantissent une expérience bancaire sécurisée et satisfaisante. Nous continuerons de fournir à nos partenaires des gammes de produits améliorées, en soutenant l'expansion régionale. »

Mastercard a été le partenaire de confiance d'ila Bank depuis le tout début, soutenant la stratégie de la banque. Les deux entreprises ont œuvré ensemble pour introduire plusieurs offres innovantes sur le marché, notamment le programme des cartes de débit multidevises, le programme de fidélité Pay with Rewards (Pay with Rewards loyalty program) et la carte de crédit co–marquée avec Gulf Air (Mastercard airline co–brand) à Bahreïn, conçue pour redéfinir les expériences bancaires et de voyage des clients. 

Depuis son établissement en 2019, ila Bank s'est consacrée à subvenir aux besoins et aux modes de vie de ses clients en offrant des solutions bancaires conçues sur mesure. La banque numérique, exclusivement mobile, appréciée à l'échelle nationale et régionale, offre actuellement une gamme de différents types de cartes de paiement, y compris des cartes de débit, de crédit et des cartes prépayées, fournissant des avantages inégalés et un système de récompense de fidélité personnalisé.

D’autres produits innovants sont accessibles via l'application primée ila, notamment les outils d'épargne numérique intelligents (« Hassala » et « Jamiya »), ainsi que « Al Kanz », le compte qui offre aux clients d'ila la chance de gagner des prix substantiels en espèces tout au long de l'année.

A propos de Mastercard :

Mastercard soutient les économies et autonomise les individus dans plus de 200 pays et territoires à travers le monde. En collaboration avec nos clients, nous construisons une économie durable où chacun peut prospérer. Nous proposons une large gamme de solutions de paiements numériques, rendant les transactions sécurisées, simples, intelligentes et accessibles. Notre technologie et notre innovation, combinées à nos partenariats et réseaux, offrent un ensemble unique de produits et services pour aider les particuliers, les entreprises et les gouvernements à réaliser leur plein potentiel. 

www.mastercard.com

Une photo accompagnant cette annonce est disponible sur le lien suivant :
https://www.globenewswire.com/NewsRoom/AttachmentNg/a838d1fe–d20b–4879–8e41–152c9e78b0a4


GLOBENEWSWIRE (Distribution ID 1001099487)

BitMEX Unveils AI-Powered VIP Trading Reports in Partnership with Hoc-trade

VICTORIA, Seychelles, May 28, 2025 (GLOBE NEWSWIRE) — BitMEX, the safest crypto exchange, today announced the launch of its new AI–driven personalised trading performance reports, exclusively available to its VIP traders. Developed in partnership with Hoc–trade, this new feature positions BitMEX as the only crypto exchange providing in–depth, customised analysis of trading behaviours, empowering its traders to pinpoint areas for improvement and optimise their strategies for enhanced profitability.

This bespoke tool delivers actionable insights derived from a trader's historical data, clearly highlighting strengths, weaknesses, and specific opportunities for refinement. By understanding their trading patterns on a granular level, VIP clients on BitMEX can now make more informed decisions, sharpen their risk management, and ultimately strive for enhanced returns – a level of trading analysis unmatched in the crypto trading space.

“At BitMEX, we are constantly seeking ways to empower our users with the most advanced tools available,” said Stephan Lutz, CEO of BitMEX. “This collaboration with Hoc–trade allows us to offer our VIP traders an unprecedented level of trading analysis, the first–of–its–kind, giving them a genuine edge in today's dynamic markets.”

Jonas Schleypen, CEO & Co–founder of Hoc–trade commented, “We’re excited to partner with BitMEX as the first crypto exchange to offer VIP Trading Reports. Given the fast–paced, high–volatility nature of crypto markets, staying focused and minimising behavioural biases is more critical than ever—and that’s exactly where the VIP Trading Report delivers value. This partnership reflects BitMEX dedication to driving innovation and raising the bar in financial crypto services.”

The BitMEX VIP Trading Report is now accessible to BitMEX VIP clients, offering an exclusive advantage in navigating the complexities of the crypto market. Traders can unlock these in–depth analytics, along with a range of other benefits like trading fee discounts, by achieving higher tiers of trading volume on the BitMEX platform or by staking BMEX Tokens, the native token of BitMEX. More details on the VIP tiers can be found here.

About BitMEX

BitMEX is the OG crypto derivatives exchange, providing professional crypto traders with a platform that caters to their needs through low latency, deep crypto native liquidity and unmatched reliability.

Since its founding, no cryptocurrency has been lost through intrusion or hacking, allowing BitMEX users to trade safely in the knowledge that their funds are secure. So too that they have access to the products and tools they require to be profitable.

BitMEX was also one of the first exchanges to publish their on–chain Proof of Reserves and Proof of Liabilities data. The exchange continues to publish this data twice a week – proving assurance that they safely store and segregate the funds they are entrusted with.

For more information on BitMEX, please visit the BitMEX Blog or www.bitmex.com, and follow Telegram, Twitter, Discord, and its online communities. For further inquiries, please contact [email protected].

About Hoc–trade
Hoc–trade is a behavioral analytics platform powered by AI, designed to help traders and institutions optimize performance by detecting and correcting emotional and cognitive biases in real time. Pioneering behavioral AI for trading, Hoc–Trade combines advanced machine learning with behavioral finance to deliver hyper–personalized insights that reveal the psychological drivers behind each trading decision — from overtrading and revenge trading to loss aversion and premature profit–taking. By transforming trading history data into actionable behavioral intelligence, Hoc–trade enables users to gain a sustainable edge through deeper self–awareness and smarter decision–making.

Through our flagship product, TradeMedic™, Hoc–trade provides hyper–personalized performance reports that help traders understand the psychological factors influencing their trading habits. TradeMedic™ AI identifies key behavioral biases but also trading strengths, offering actionable insights that drive better decision–making and support long–term trading success. For more information on Hoc–Trade and TradeMedic, please visit www.hoc–trade.com, and follow us on Twitter, LinkedIn, and Instagram. For further inquiries, please contact info@hoc–trade.com.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/42e4b062–dad7–4715–ad2d–cb4fcfd8a25e

https://www.globenewswire.com/NewsRoom/AttachmentNg/89148f9b–726d–44a3–bb93–91752f44d1e5


GLOBENEWSWIRE (Distribution ID 1001099401)